GlaxoSmithKline (GSK) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS
GlaxoSmithKline (NYSE:GSK) issued its earnings results on Wednesday. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.03, Morningstar.com reports. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%. The firm had revenue of $10.14 billion for the quarter, compared to analysts’ expectations of $9.89 billion.
Shares of GlaxoSmithKline (NYSE:GSK) traded up $0.92 during trading hours on Thursday, hitting $36.95. The company’s stock had a trading volume of 2,023,564 shares, compared to its average volume of 5,173,329. GlaxoSmithKline has a fifty-two week low of $34.52 and a fifty-two week high of $44.53. The stock has a market capitalization of $91,350.00, a price-to-earnings ratio of 42.94, a PEG ratio of 2.31 and a beta of 0.98. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96.
Several brokerages have recently issued reports on GSK. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Wednesday, October 18th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, October 18th. Bank of America cut GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. ValuEngine lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, UBS Group reiterated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday, January 15th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $38.57.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.